NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on March 4, ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

In this article, we will look at the 10 Best Performing Pharma Stocks So Far in 2025. What’s Going on in the Pharma Sector?

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of ...

Pfizer recently announced better-than-expected Q4 results. Products picked up with the acquisition of Seagen were big contributors to growth, including Adcetris and Padcev. So were other acquired ...

Pfizer has agreed to pay $59,746,277.54 ... to health care providers to induce them to prescribe Nurtec ODT (Nurtec), a prescription medication for the treatment of migraine headaches. As part of the ...

Pfizer Inc. (NYSE:PFE – Free Report ... and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs ...